4 min read
A Look Back at 2022
What a year 2022 turned out to be! It was a year of growth and expansion, with many exciting successes for Selexis as...
What a year 2022 turned out to be! It was a year of growth and expansion, with many exciting successes for Selexis as...
Over the past 30 years, biologic therapeutics have significantly transformed treatment options for millions of...
Biopharmaceutical companies are increasingly seeking service providers to help them reduce biologics manufacturing...
For more than 20 years, Selexis has been helping its partners predictably, rapidly and cost-effectively generate...
Just as it is well understood that silicon chips must be made in sophisticated factories with the appropriate...
With 10 years of university experience, a PhD and a hunger for new challenges and experiences, I left Finland to pursue...
YEMI ONAKUNLE: My work helping to lead new business development efforts at Selexis continues to challenge and inspire...
In early April, we were thrilled to announce that the fifth Selexis SUREtechnology-generated product was approved in...
As a child growing up in Nigeria, I had first-hand experience of the suffering caused by debilitating diseases such as...
In building a marketing campaign for our lead technology, we wanted something that would reflect and represent the...
The important thing is not to stop questioning. Curiosity has its own reason for existing. – Albert Einstein
As an...
In 2001, I co-founded Selexis with prize money that I won from the de Vigier Foundation in Switzerland followed by the...
As a young scientist and entrepreneur, I understood early in my career just how important it is to stay ahead of the...
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Copyright© 2023 Selexis SA. All Rights Reserved.